Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout #pharmaceutical #advertising

Posted On Aug 13 2017 by

#onyx pharma # Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout SOUTH SAN FRANCISCO, Calif. ( TheStreet ) — Every biotech CEO wants to say they bought an asset for X and sold it for 10X, yet few top executives manage to create value on this mammoth scale. Onyx Pharmaceuticals’ ( ONXX ) CEO Tony Coles just did it. The 10X is Amgen ( AMGN ) paying $10 billion in cash ($125 per share) to acquire Onyx. The deal, much discussed and analyzed since June, was finally announced Sunday night. But Amgen wouldn’t be buying Onyx …


Drug company R – D: Nowhere near $1 billion #biochem #pharma

Posted On Aug 9 2017 by

#drug research companies # Drug company R D argument for half a century, but the specific source of the $1 billion claim is a 2003 study published in the Journal of Health Economics by economists Joseph DiMasi of Tufts, Ronald W. Hansen of the University of Rochester, and Henry Grabowski of Duke. I will henceforth refer to this team as the Tufts Center group, because they were working out of the (drug-company-funded ) Tufts Center for the Study of Drug Development. The Tufts Center group “obtained from a survey of 10 pharmaceutical firms” the research and development costs of 68 …


Horizon Pharma Bids $3 Billion For Depomed #pharmaceutical #manufacturing #industry

Posted On Aug 7 2017 by

#horizon pharma # Ireland’s Horizon Pharma launches hostile, $3 billion bid for U.S. rival Ireland s Horizon Pharma is bringing its $3 billion takeover offer for U.S. rival Depomed directly to the company s shareholders after being rebuffed in its attempts to negotiate with Depomed s management. Horizon s HZNP hostile bid for Depomed DEPO . announced on Tuesday. values the Newark, Calif.-based specialty pharmaceutical company at $29.25 per share, which represents a 42% premium over Depomed s Monday closing price. Depomed s share price jumped nearly 40% on the news of Horizon s offer. The Irish manufacturer of drugs …


Drug company R – D: Nowhere near $1 billion #jobs #in #the #pharmaceutical #industry

Posted On Aug 2 2017 by

#drug research companies # Drug company R D argument for half a century, but the specific source of the $1 billion claim is a 2003 study published in the Journal of Health Economics by economists Joseph DiMasi of Tufts, Ronald W. Hansen of the University of Rochester, and Henry Grabowski of Duke. I will henceforth refer to this team as the Tufts Center group, because they were working out of the (drug-company-funded ) Tufts Center for the Study of Drug Development. The Tufts Center group “obtained from a survey of 10 pharmaceutical firms” the research and development costs of 68 …


Dublin-based Actavis to buy Forest Labs for $25 billion #pharma #sales #job

Posted On Aug 1 2017 by

#forest pharma # Dublin-based Actavis to buy Forest Labs for $25 billion Actavis. the world’s second-largest generic-drug maker by market value, is to buy Forest Laboratories in a cash and stock deal valued at about $25 billion. Actavis will pay the equivalent of $89.48 per share, representing a premium of 25 per cent to Forest’s Friday close. The offer comprises $26.04 in cash and 0.3306 Actavis shares for every Forest share. Forest had a market value of $19.3 billion at the close of trading last Friday. Dublin-headquartered Actavis was the most active buyer of drug companies over the past three …


Big Pharma Pockets $711 Billion in Profits by Price-Gouging Taxpayers and Seniors #thaiger #pharma

Posted On Jul 27 2017 by

#how big is the pharmaceutical industry # Big Pharma Pockets $711 Billion in Profits by Price-Gouging Taxpayers and Seniors Washington, DC – The 11 largest drug companies took $711.4 billion in profits over the 10 years ending in 2012, according to an analysis of corporate filings by Health Care for America Now (HCAN). The global pharmaceutical industry derived much of that profit from price-gouging the Medicare Part D prescription drug program for seniors and people with disabilities. Americans pay significantly more than any other country for the exact same drugs. In 2012 alone, the drug companies’ profits reached $83.9 billion, …


Teva Buys Drug Rival, Barr, for $ Billion #drug #chemistry

Posted On Jul 22 2017 by

#barr pharma # The New York Times Teva Buys Drug Rival, Barr, for $7.46 Billion July 19, 2008 Teva Pharmaceutical Industries said Friday that it would buy a rival generic drug maker, Barr Pharmaceuticals, for $7.46 billion to expand in both the United States and Europe. The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players. Teva, the world’s largest generic drug company, plans to buy Barr for $66.50 a share in cash and stock. The price represents a 42 percent premium …


Teva Buys Drug Rival, Barr, for $ Billion #akela #pharma

Posted On Jul 8 2017 by

#barr pharma # The New York Times Teva Buys Drug Rival, Barr, for $7.46 Billion July 19, 2008 Teva Pharmaceutical Industries said Friday that it would buy a rival generic drug maker, Barr Pharmaceuticals, for $7.46 billion to expand in both the United States and Europe. The deal is the latest in a wave of consolidation in the generic-drug sector that some analysts suspect will result in only a handful of major global players. Teva, the world’s largest generic drug company, plans to buy Barr for $66.50 a share in cash and stock. The price represents a 42 percent premium …


Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout #top #pharma #companies

Posted On Jul 8 2017 by

#onyx pharma # Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout SOUTH SAN FRANCISCO, Calif. ( TheStreet ) — Every biotech CEO wants to say they bought an asset for X and sold it for 10X, yet few top executives manage to create value on this mammoth scale. Onyx Pharmaceuticals’ ( ONXX ) CEO Tony Coles just did it. The 10X is Amgen ( AMGN ) paying $10 billion in cash ($125 per share) to acquire Onyx. The deal, much discussed and analyzed since June, was finally announced Sunday night. But Amgen wouldn’t be buying Onyx …


Drug company R – D: Nowhere near $1 billion #pharma.com

Posted On Jul 5 2017 by

#drug research companies # Drug company R D argument for half a century, but the specific source of the $1 billion claim is a 2003 study published in the Journal of Health Economics by economists Joseph DiMasi of Tufts, Ronald W. Hansen of the University of Rochester, and Henry Grabowski of Duke. I will henceforth refer to this team as the Tufts Center group, because they were working out of the (drug-company-funded ) Tufts Center for the Study of Drug Development. The Tufts Center group “obtained from a survey of 10 pharmaceutical firms” the research and development costs of 68 …